Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 292

1.

Combined immunization with adjuvant molecules poly(I:C) and anti-CD40 plus a tumor antigen has potent prophylactic and therapeutic antitumor effects.

Llopiz D, Dotor J, Zabaleta A, Lasarte JJ, Prieto J, Borrás-Cuesta F, Sarobe P.

Cancer Immunol Immunother. 2008 Jan;57(1):19-29. Epub 2007 Jun 13.

PMID:
17564702
2.

Induction of potent and long-lasting CD4 and CD8 T-cell responses against hepatitis C virus by immunization with viral antigens plus poly(I:C) and anti-CD40.

Zabaleta A, Arribillaga L, Llopiz D, Dotor J, Lasarte JJ, Prieto J, Borrás-Cuesta F, Esteban JI, Quer J, Vayreda F, Sarobe P.

Antiviral Res. 2007 Apr;74(1):25-35. Epub 2007 Jan 22.

PMID:
17275104
3.

Successful tumor eradication was achieved by collaboration of augmented cytotoxic activity and anti-angiogenic effects following therapeutic vaccines containing helper-activating analog-loaded dendritic cells and tumor antigen DNA.

Teramoto K, Kontani K, Fujita T, Ozaki Y, Sawai S, Tezuka N, Fujino S, Itoh Y, Taguchi O, Kannagi R, Ogasawara K.

Cancer Immunol Immunother. 2007 Mar;56(3):331-42. Epub 2006 Aug 5.

PMID:
16896967
4.

Th1 cell adjuvant therapy combined with tumor vaccination: a novel strategy for promoting CTL responses while avoiding the accumulation of Tregs.

Zhang Y, Wakita D, Chamoto K, Narita Y, Matsubara N, Kitamura H, Nishimura T.

Int Immunol. 2007 Feb;19(2):151-61. Epub 2006 Dec 22.

PMID:
17189593
5.

Peptide inhibitors of transforming growth factor-beta enhance the efficacy of antitumor immunotherapy.

Llopiz D, Dotor J, Casares N, Bezunartea J, Díaz-Valdés N, Ruiz M, Aranda F, Berraondo P, Prieto J, Lasarte JJ, Borrás-Cuesta F, Sarobe P.

Int J Cancer. 2009 Dec 1;125(11):2614-23. doi: 10.1002/ijc.24656.

8.

Immunization against a dominant tumor antigen abrogates immunogenicity of the tumor.

Makki A, Weidt G, Blachere NE, Lefrançois L, Srivastava PK.

Cancer Immun. 2002 Apr 16;2:4.

9.

Individual analysis of mice vaccinated against a weakly immunogenic self tumor-specific antigen reveals a correlation between CD8 T cell response and antitumor efficacy.

Rosato A, Zoso A, Milan G, Macino B, Dalla Santa S, Tosello V, Di Carlo E, Musiani P, Whalen RG, Zanovello P.

J Immunol. 2003 Nov 15;171(10):5172-9.

10.

CD40 and CD70 co-stimulate a potent in vivo antitumor T cell response.

Nieland JD, Graus YF, Dortmans YE, Kremers BL, Kruisbeek AM.

J Immunother. 1998 May;21(3):225-36.

PMID:
9610915
11.

Immuno-viral therapy of brain tumors by combination of viral therapy with cancer vaccination using a replication-conditional HSV.

Toda M, Iizuka Y, Kawase T, Uyemura K, Kawakami Y.

Cancer Gene Ther. 2002 Apr;9(4):356-64.

12.

Protective antitumor activity through dendritic cell immunization is mediated by NK cell as well as CTL activation.

Kim KD, Kim JK, Kim SJ, Choe IS, Chung TH, Choe YK, Lim JS.

Arch Pharm Res. 1999 Aug;22(4):340-7.

PMID:
10489871
13.

An indispensable role of type-1 IFNs for inducing CTL-mediated complete eradication of established tumor tissue by CpG-liposome co-encapsulated with model tumor antigen.

Wakita D, Chamoto K, Zhang Y, Narita Y, Noguchi D, Ohnishi H, Iguchi T, Sakai T, Ikeda H, Nishimura T.

Int Immunol. 2006 Mar;18(3):425-34. Epub 2006 Jan 13.

PMID:
16415100
14.

Induction of antitumor immunity by indomethacin.

Morecki S, Yacovlev E, Gelfand Y, Trembovler V, Shohami E, Slavin S.

Cancer Immunol Immunother. 2000 Feb;48(11):613-20.

PMID:
10663608
15.

Allogeneic GM-CSF-secreting tumor cell immunotherapies generate potent anti-tumor responses comparable to autologous tumor cell immunotherapies.

Li B, Simmons A, Du T, Lin C, Moskalenko M, Gonzalez-Edick M, VanRoey M, Jooss K.

Clin Immunol. 2009 Nov;133(2):184-97. doi: 10.1016/j.clim.2009.07.008. Epub 2009 Aug 7.

PMID:
19664962
16.

Potent CTL induction by a whole cell pertussis vaccine in anti-tumor peptide immunotherapy.

Yano A, Komatsu T, Ishibashi M, Udaka K.

Microbiol Immunol. 2007;51(7):685-99.

17.
18.

Vaccination with liposome--DNA complexes elicits enhanced antitumor immunity.

U'Ren L, Kedl R, Dow S.

Cancer Gene Ther. 2006 Nov;13(11):1033-44. Epub 2006 Jul 14.

PMID:
16841080
19.

Adenovirus-mediated gene transfer of interleukin-23 shows prophylactic but not therapeutic antitumor effects.

Jin HT, Youn JI, Choi SY, Seo SH, Park SH, Song MY, Yang SH, Sung YC.

Cancer Gene Ther. 2008 Nov;15(11):693-702. doi: 10.1038/cgt.2008.41. Epub 2008 Jul 4.

PMID:
18600259
20.

Induction of antigen-specific cytotoxic T lymphocytes by immunization with negatively charged soluble antigen through scavenger receptor-mediated delivery.

Yamasaki Y, Ikenaga T, Otsuki T, Nishikawa M, Takakura Y.

Vaccine. 2007 Jan 2;25(1):85-91. Epub 2006 Jul 31.

PMID:
16956699

Supplemental Content

Support Center